The chimeric antigen receptor used in our studies is comprised of T cell intracellular signaling domains, derived from CD3ζ and CD28, linked to an extracellular single chain variable fragment specific for the tumor antigen, ErbB2 (Her2). The gene discussed is ERBB2; the disease is neoplasm.